P17-22. Impact of rare adenovirus seroprevalence on HIV-1 acquisition in the Step study

por Maxfield, LF, King, SL, Riggs, AM, Dilan, R, LaPorte, A, Hural, J, McElrath, MJ, Goudsmit, J, Barouch, DH
Publicado 2009

OA05-06 LB. First-in-human Phase 1 safety and immunigenicity of an adenovirus serotype 26 HIV-1 vaccine vector

por Baden, LR, Dolin, R, O'Brien, KL, Abbink, P, La Porte, A, Seaman, MS, Choi, E, Tucker, R, Weitjens, M, Pau, MG, Goudsmit, J, Barouch, DH
Publicado 2009